RWE Tops DAX Revenue Growth While a Urenco Exit Takes Shape

RWE led all DAX groups on top-line expansion in the third quarter of 2026, yet booked a negative operating result over the same stretch — a split verdict that puts the quality of its earnings, rather than the pace of its sales, at the centre of the investment case. The findings come from an EY analysis published today.

Revenue climbed 46% year on year, the fastest growth among the DAX companies EY examined. RWE was also one of four groups to post a negative result before interest and taxes. Earnings per share fell to a loss of EUR 2.39 for the quarter, reversing a profit of EUR 1.17 in the same period a year earlier.

That divergence means the headline sales figure answers only part of the profitability question. A convincing operating story would require the larger business volume to translate into positive reported operating profit, not merely a bigger top line.

Adjusted figures tell a friendlier story

The nine-month numbers released on Wednesday offer a brighter read on an adjusted basis. EBITDA reached EUR 4.575 billion, up 35% on the prior-year level. That supports the case for underlying momentum over the longer reporting period, provided the strength carries into subsequent quarters. Guidance for the full year was left unchanged, framing the existing set of expectations.

Should investors sell immediately? Or is it worth buying Rwe?

Heavy spending puts financing in the spotlight

RWE is investing heavily alongside that earnings growth. Net capital expenditure across the first nine months came to EUR 10.7 billion, and plants with 13.5 gigawatts of capacity were under construction worldwide. The build-out opens a growth avenue if projects proceed as planned, though it also ties up capital and raises the weight of financing costs — making debt reduction as important to shareholders as operating profit.

Net debt stood at EUR 17 billion at the end of the quarter. By year-end, RWE is targeting net liabilities of around EUR 12 billion. The investment thesis thus rests on two pillars: rising operating earnings and financial discipline during the expansion. It becomes more persuasive if RWE hits its deleveraging targets and pairs the strong revenue growth with better reported profitability.

A possible exit from Urenco

Separately, RWE and E.ON are moving closer to divesting their stake in uranium enricher Urenco. Media reports say the two German utilities want to sell because the holding has lost strategic value following Germany's nuclear phase-out, with Urenco's growing military nuclear activities adding a further motive. Reported deliberations by the federal government open a possible exit route — if they turn into a binding purchase.

Through Uranit UK Limited, RWE and E.ON together hold one third of Urenco. The UK and the Netherlands each own another third, so a federal acquisition would concern the German companies' joint stake. According to Reuters, Berlin is weighing the purchase for geostrategic reasons. Both the government and the companies declined to comment.

Urenco runs a uranium enrichment plant in Gronau. Per a report in the Süddeutsche Zeitung, the company is set to produce highly enriched uranium for British nuclear submarines — an orientation that media reports cite, alongside the phase-out, as a reason behind the German shareholders' desire to sell.

Rwe at a turning point? This analysis reveals what investors need to know now.

Budget line, price and split still unconfirmed

A new expenditure item of EUR 4 billion for the acquisition and holding of energy stakes appears in the draft budget for 2027. Media reports link that allocation to Urenco, though the assignment and a possible purchase price remain unconfirmed.

For RWE's valuation, the concrete agreement is what matters. A cash inflow could strengthen financial flexibility if Berlin does buy and the terms provide a corresponding proceeds share. How any sum would be divided between RWE and E.ON is open, and firm statements on the financial benefit require details on price and allocation.

The stock rose 1.1% today, tracking the transaction reports positively. The decisive test for investors lies in how the sale deliberations unfold: only a confirmed agreement with a quantified RWE share would turn the strategic exit prospect into a financial effect that can be properly valued. Until then, the appeal of the potential deal rests on conditions that have yet to be settled.

Ad

Rwe Stock: New Analysis - 14 November

Fresh Rwe information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Rwe analysis...